Accordingly, the large majority of recombinant adeno-associated virus (rAAV)-based therapies—which account for most gene therapies—are still produced with a method developed more than two ...

To address this bottleneck, Seymour and colleagues developed a new way to manufacture rAAV using the ‘helper’ adenovirus technique. “We focused on helper-adenovirus production as it is ...